Posted 22 August, 2026
UCD Post-doctoral Research Fellow Level 1, UCD School of Medicine, Temporary 6 months
University College Dublin
Dublin, Dublin, Ireland
Temporary
Reference: 1012325459
UCD Post-doctoral Research Fellow Level 1, UCD School of Medicine, Temporary 6 months
Applications are invited for a temporary post of a UCD Post-doctoral Research Fellow Level 1 within UCD School of Medicine.
Our work is focused on leveraging epigenomic and functional genomics methods to find new therapeutic avenues in difficult-to-treat cancers. With a particular focus on haematological malignancies, we are using CRISPR-Cas9 screening to uncover therapy resistance mechanisms, and to identify novel sensitizing drug targets. In close collaboration with clinical oncologists, we are also striving to understand the epigenomic differences that underlie drug sensitivity, both inter- and intra-patient. The advent of low-input and single-cell epigenomics techniques provides a hugely promising therapeutic opportunity in this area. The group is affiliated with the UCD School of Medicine and the UCD Conway Institute of Biomolecular and Biomedical Research. Our group is located in the Conway Institute, an interdisciplinary research centre exploring the mechanisms of health and disease towards the development of preventative strategies and novel diagnostic and therapeutic solutions.
Project description: Multiple Myeloma (MM) is an incurable disease with an extremely poor 10-year survival rate (~29%). It is caused by uncontrolled proliferation of the plasma cells. Over the last decade there have been several advances in its treatment, such as immunomodulators and proteasome inhibitors, however it remains incurable.
This project will identify key MM-driving enhancers by epigenetic analysis in a combination of in vitro and primary patient samples. This will primarily involve wet-lab experimentation using genomics assays (4C-seq, CUT&RUN/CUT&Tag). This inter-disciplinary project will involve close collaboration with clinical haematologists at St. Vincent's Hospital, wet-lab & computational biologists and international research groups. The successful applicant will gain experience in next-generation sequencing technologies and genomics assays.
Fixed Salary: €47,273 Per Annum
Closing date: 12:00 noon (local Irish time) on 27 August 2026.
Applications must be submitted by the closing date and time specified. Any applications which are still in progress at the closing time of 12:00 noon (Local Irish Time) on the specified closing date will be cancelled automatically by the system. UCD are unable to accept late applications.
UCD do not require assistance from Recruitment Agencies. Any CV's submitted by Recruitment Agencies will be returned.
The PD1 position is intended for early-stage researchers, either just after completion of a PhD or for someone entering a new area for the first time. If you have already completed your PD1 stage in UCD or will soon complete a PD1, or you are an external applicant whose total Postdoctoral experience, inclusive of the duration of the advertised post, would exceed 4 years, you should not apply and should refer to PD2 posts instead.
Applications are invited for a temporary post of a UCD Post-doctoral Research Fellow Level 1 within UCD School of Medicine.
Our work is focused on leveraging epigenomic and functional genomics methods to find new therapeutic avenues in difficult-to-treat cancers. With a particular focus on haematological malignancies, we are using CRISPR-Cas9 screening to uncover therapy resistance mechanisms, and to identify novel sensitizing drug targets. In close collaboration with clinical oncologists, we are also striving to understand the epigenomic differences that underlie drug sensitivity, both inter- and intra-patient. The advent of low-input and single-cell epigenomics techniques provides a hugely promising therapeutic opportunity in this area. The group is affiliated with the UCD School of Medicine and the UCD Conway Institute of Biomolecular and Biomedical Research. Our group is located in the Conway Institute, an interdisciplinary research centre exploring the mechanisms of health and disease towards the development of preventative strategies and novel diagnostic and therapeutic solutions.
Project description: Multiple Myeloma (MM) is an incurable disease with an extremely poor 10-year survival rate (~29%). It is caused by uncontrolled proliferation of the plasma cells. Over the last decade there have been several advances in its treatment, such as immunomodulators and proteasome inhibitors, however it remains incurable.
This project will identify key MM-driving enhancers by epigenetic analysis in a combination of in vitro and primary patient samples. This will primarily involve wet-lab experimentation using genomics assays (4C-seq, CUT&RUN/CUT&Tag). This inter-disciplinary project will involve close collaboration with clinical haematologists at St. Vincent's Hospital, wet-lab & computational biologists and international research groups. The successful applicant will gain experience in next-generation sequencing technologies and genomics assays.
Fixed Salary: €47,273 Per Annum
Closing date: 12:00 noon (local Irish time) on 27 August 2026.
Applications must be submitted by the closing date and time specified. Any applications which are still in progress at the closing time of 12:00 noon (Local Irish Time) on the specified closing date will be cancelled automatically by the system. UCD are unable to accept late applications.
UCD do not require assistance from Recruitment Agencies. Any CV's submitted by Recruitment Agencies will be returned.
The PD1 position is intended for early-stage researchers, either just after completion of a PhD or for someone entering a new area for the first time. If you have already completed your PD1 stage in UCD or will soon complete a PD1, or you are an external applicant whose total Postdoctoral experience, inclusive of the duration of the advertised post, would exceed 4 years, you should not apply and should refer to PD2 posts instead.
